Mishcon de Reya page structure
Site header
Main menu
Main content section

Inside Life Sciences

Issue 3: November 2017

Inside Life Sciences
Infliximab: battle of the biosimilars Post

Infliximab: battle of the biosimilars

On 23 May, the CMA issued a statement of objections, which is a provisional finding that Merck Sharp & Dohme Limited (MSD) has breached UK competition law by abusing its dominant position.

Health apps: Patient empowerment, but at what cost? Post

Health apps: Patient empowerment, but at what cost?

With the NHS increasingly prescribing health apps that assist with the management of particular health conditions, and Health Secretary, Jeremy Hunt, revealing ambitious plans to provide patients with access to their medical records through apps by 2018

Restructuring doesn’t have to be a messy ordeal Post

Restructuring doesn’t have to be a messy ordeal

A company's decision to restructure can be prompted by a number of different things – it could be as a consequence of success, the result of disagreements, or simply because of commercial imperatives.

Previous Issues

Prev
How can we help you?
Help

How can we help you?

Subscribe: I'd like to keep in touch

If your enquiry is urgent please call +44 20 3321 7000

Crisis Hotline

I'm a client

I'm looking for advice

Something else